Citigroup Inc Foghorn Therapeutics Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 18,345 shares of FHTX stock, worth $85,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,345

Previous 5,601 227.53%

Holding current value

$85,304

Previous $32,000 431.25%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.8 - $9.99 $61,171 - $127,312	12,744 Added 227.53%	18,345 $170,000
Q2 2024 Aug 12, 2024	BUY	$5.05 - $8.0 $11,190 - $17,728	2,216 Added 65.47%	5,601 $32,000
Q1 2024 May 10, 2024	BUY	$2.82 - $7.94 $1,274 - $3,588	452 Added 15.41%	3,385 $22,000
Q4 2023 Feb 09, 2024	BUY	$2.94 - $6.76 $7,020 - $16,142	2,388 Added 438.17%	2,933 $18,000
Q3 2023 Nov 09, 2023	SELL	$5.0 - $9.87 $31,165 - $61,519	-6,233 Reduced 91.96%	545 $2,000
Q2 2023 Aug 10, 2023	BUY	$5.37 - $8.84 $33,836 - $55,700	6,301 Added 1320.96%	6,778 $47,000
Q1 2023 May 11, 2023	SELL	$4.66 - $8.99 $876 - $1,690	-188 Reduced 28.27%	477 $2,000
Q4 2022 Feb 09, 2023	BUY	$5.44 - $9.46 $1,958 - $3,405	360 Added 118.03%	665 $4,000
Q3 2022 Nov 10, 2022	SELL	$7.52 - $18.01 $7,474 - $17,901	-994 Reduced 76.52%	305 $3,000
Q2 2022 Aug 10, 2022	BUY	$8.48 - $16.84 $4,036 - $8,015	476 Added 57.84%	1,299 $18,000
Q1 2022 May 12, 2022	SELL	$8.87 - $22.1 $36,934 - $92,024	-4,164 Reduced 83.5%	823 $13,000
Q4 2021 Feb 10, 2022	BUY	$10.79 - $22.87 $29,737 - $63,029	2,756 Added 123.53%	4,987 $114,000
Q3 2021 Nov 10, 2021	BUY	$8.33 - $15.02 $18,584 - $33,509	2,231 New	2,231 $31,000

Others Institutions Holding FHTX

# of Institutions

Shares Held

33.3M

Call Options Held

8.7K

Put Options Held

2.4K

View Full List

About Foghorn Therapeutics Inc.

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $194M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

More about FHTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account